



# Rising Hemoglobin A<sub>1c</sub> in the Nondiabetic Range Predicts Progression of Type 1 Diabetes As Well As Oral Glucose Tolerance Tests

Diabetes Care 2022;45:2342–2349 | <https://doi.org/10.2337/dc22-0828>

Kendra Vehik,<sup>1</sup> David Boulware,<sup>1</sup> Michael Killian,<sup>2</sup> Marian Rewers,<sup>3</sup> Richard McIndoe,<sup>4</sup> Jorma Toppari,<sup>5</sup> Åke Lernmark,<sup>6</sup> Beena Akolkar,<sup>7</sup> Anette-G. Ziegler,<sup>8</sup> Henry Rodriguez,<sup>9</sup> Desmond A. Schatz,<sup>10</sup> Jeffrey P. Krischer,<sup>1</sup> and William Hagopian,<sup>2</sup> for the TrialNet Study Group and TEDDY Study Group\*

## OBJECTIVE

Biomarkers predicting risk of type 1 diabetes (stage 3) among children with islet autoantibodies are greatly needed to prevent diabetic ketoacidosis and facilitate prevention therapies.

## RESEARCH DESIGN AND METHODS

Children in the prospective The Environmental Determinants of Diabetes in the Young (TEDDY) study ( $n = 707$ ) with confirmed diabetes-associated autoantibodies (GAD antibody, IA-2A, and/or insulin autoantibody) and two or more HbA<sub>1c</sub> measurements were followed to diabetes or median age 11.1 years. Once confirmed autoantibody positive, HbA<sub>1c</sub> was measured quarterly. Cox models and receiver operative characteristic curve analyses revealed the prognostic utility for risk of stage 3 on a relative HbA<sub>1c</sub> increase from the baseline visit or an oral glucose tolerance test (OGTT) 2-h plasma glucose (2-hPG). This HbA<sub>1c</sub> approach was then validated in the Type 1 Diabetes TrialNet Pathway to Prevention Study (TrialNet) ( $n = 1,190$ ).

## RESULTS

A 10% relative HbA<sub>1c</sub> increase from baseline best marked the increased risk of stage 3 in TEDDY (74% sensitive; 88% specific). Significant predictors of risk for HbA<sub>1c</sub> change were age and HbA<sub>1c</sub> at the baseline test, genetic sex, maximum number of autoantibodies, and maximum rate of HbA<sub>1c</sub> increase by time of change. The multivariable model featuring a HbA<sub>1c</sub>  $\geq 10\%$  increase and these additional factors revealed increased risk of stage 3 in TEDDY (hazard ratio [HR] 12.74, 95% CI 8.7–18.6,  $P < 0.0001$ ) and TrialNet (HR 5.09, 95% CI 3.3–7.9,  $P < 0.0001$ ). Furthermore, the composite model using HbA<sub>1c</sub>  $\geq 10\%$  increase performed similarly to an OGTT 2-hPG composite model (TEDDY area under the curve [AUC] 0.88 and 0.85, respectively) and to the HbA<sub>1c</sub> model in TrialNet (AUC 0.82).

## CONCLUSIONS

An increase of  $\geq 10\%$  in HbA<sub>1c</sub> from baseline is as informative as OGTT 2-hPG in predicting risk of stage 3 in youth with genetic risk and diabetes-associated autoantibodies.

The incidence of autoimmune type 1 diabetes rose 1.4% annually from 2002 to 2012 in youth  $< 20$  years of age, with the greatest increase in those  $< 5$  years of age (1).

<sup>1</sup>Health Informatics Institute, Morsani College of Medicine, University of South Florida, Tampa, FL  
<sup>2</sup>Pacific Northwest Research Institute, Seattle, WA

<sup>3</sup>Barbara Davis Center for Childhood Diabetes, University of Colorado, Aurora, CO

<sup>4</sup>Center for Biotechnology and Genomic Medicine, Medical College of Georgia, Georgia Regents University, Augusta, GA

<sup>5</sup>Research Centre for Integrative Physiology and Pharmacology, Institute of Biomedicine, University of Turku, and Department of Pediatrics, Turku University Hospital, Turku, Finland

<sup>6</sup>Department of Clinical Sciences, Lund University/Clinical Research Centre, Skane University Hospital, Malmö, Sweden

<sup>7</sup>National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD

<sup>8</sup>Institute of Diabetes Research, Helmholtz Zentrum München, and Klinikum rechts der Isar, Technische Universität München, and Forschergruppe Diabetes e.V. Neuherberg, Germany

<sup>9</sup>USF Diabetes and Endocrinology Center, Morsani College of Medicine, University of South Florida, Tampa, FL

<sup>10</sup>Diabetes Center of Excellence, University of Florida, Gainesville, FL

Corresponding authors: Kendra Vehik, [kendra.vehik@epi.usf.edu](mailto:kendra.vehik@epi.usf.edu), and William Hagopian, [wah@uw.edu](mailto:wah@uw.edu)

Received 27 April 2022 and accepted 15 July 2022

This article contains supplementary material online at <https://doi.org/10.2337/figshare.20405490>.

\*A complete list of the TrialNet Study Group and TEDDY Study Group can be found in the supplementary material online.

© 2022 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at <https://www.diabetesjournals.org/journals/pages/license>.

Type 1 diabetes has been widely shown to be predictable by islet autoantibody testing (2–4). These autoantibodies may be present long before the onset of dysglycemia or clinical diabetes (stage 3) and do not accurately predict when hyperglycemia and the need for prompt insulin therapy will occur. Advanced knowledge of this timing is of key importance to enable close glycemic monitoring and early detection of symptoms to effectively prevent diabetic ketoacidosis at onset (5,6). Further, this approach enables application of immunotherapy at a time when more  $\beta$ -cell mass remains than at stage 3.

Many types of biomarkers have been evaluated to predict timing of disease progression in autoantibody-positive children (7,8). Along with HLA DR-DQ, there are >50 other genetic loci significantly associated with type 1 diabetes; yet, even combinations have not allowed prediction of disease progression in individuals (9). We now know of autoantibodies to  $\geq 10$   $\beta$ -cell antigens, but most are secondary or spreading autoantigens, and their patterns, epitopes, and isotypes have not yielded sufficiently informative timing information. Neither measures of islet-specific CD4<sup>+</sup> and CD8<sup>+</sup> T cells accessible in peripheral blood (10) nor circulating metabolites (11) have provided consistent individual measures of disease progression. Even declining C-peptide is a late change that is not sensitive in the preonset period (12).

Evidence has revealed that dysglycemia occurs months to years prior to stage 3, and monitoring glycemia may offer reliable prediction of stage 3. However, fasting blood glucose, while part of standardized guidelines, may be insensitive to predict stage 3 (13). Random self-monitored capillary blood glucose levels are sometimes useful, but compliance can be difficult for families without a current patient with diabetes, where most new cases will arise. Oral glucose tolerance tests (OGTTs), as a sensitive measure of dysglycemia, are an important part of the official diagnostic guidelines (14), but their extended time course is challenging to complete in standard pediatric clinic settings. Continuous glucose monitors reveal detailed glycemia levels, excursions, and patterns, and can accurately predict impending stage 3 (15), but require greater clinician involvement and greater device costs.

Glycohemoglobin (HbA<sub>1c</sub>) measurements require only a single fingerstick sample, are

inexpensive, widely available, and familiar to clinicians. The American Diabetes Association and World Health Organizations, along with an International Expert Committee, have established an HbA<sub>1c</sub> value for diagnosis of diabetes of  $\geq 6.5\%$ , largely based on adult type 2 diabetes data (14). However, since HbA<sub>1c</sub> measures average blood glucose over the prior 6 to 12 weeks, it cannot reflect acute changes in the glycemic milieu. For this reason, single HbA<sub>1c</sub> measurements have not been useful, even at onset, to diagnose childhood diabetes in most settings (16).

Rather than a single measure, increases in HbA<sub>1c</sub> were first suggested to be informative in 2006. There was a significant HbA<sub>1c</sub> increase among autoantibody-positive progressors to stage 3 from a baseline of 5.1%, although no set criteria were established, perhaps because only annual HbA<sub>1c</sub> data were available (17). More recently, HbA<sub>1c</sub> values were shown to average 5.7% in 10 progressors versus 5.3% in 10 nonprogressors, while continuous glucose monitoring (CGM) and self-monitoring of blood glucose (SMBG) were deemed more useful (18). A report from the Finnish Diabetes Prediction and Prevention (DIPP) study suggested a 10% increase was predictive (19), although another study found a 10% increase insufficient and recommended using a 20% increase (20).

Given these findings, the current analysis assessed whether a relative change in HbA<sub>1c</sub> over time was predictive of stage 3 in an international multisite pediatric population and further validated in a large, independent study of relatives to patients with type 1 diabetes. The specific aims were to 1) evaluate whether a change in HbA<sub>1c</sub> predicted risk of stage 3; 2) identify specific diabetes-related risk factors in TEDDY that predict a change in HbA<sub>1c</sub>; 3) determine whether a rapid change in HbA<sub>1c</sub> increased the estimated risk of stage 3; and 4) compare HbA<sub>1c</sub>-based to OGTT-based composite predictors to assess their relative merits.

## RESEARCH DESIGN AND METHODS

### Study Design and Participants

The primary population is derived from the multinational TEDDY prospective cohort (21) and the validating population from the Type 1 Diabetes TrialNet Pathway to Prevention Study (TrialNet) (22). In both studies, eligible participants are

<21 years of age, are positive for one or more islet autoantibodies, and have undergone at least two serial HbA<sub>1c</sub> measurements. Stage 3 type 1 diabetes is defined using the American Diabetes Association criteria (14). The primary objective assessed the prognostic utility of a relative change in HbA<sub>1c</sub> on risk of stage 3. Relative change in HbA<sub>1c</sub> is the calculated percentage change at each serial measure up to the stage 3 diagnosis from the baseline HbA<sub>1c</sub> measure. HbA<sub>1c</sub> measures collected at diagnosis or postdiagnosis are excluded. The details of these two studies have previously been described (22,23).

### TEDDY Study

Children are screened at birth for high-risk HLA genotypes (24) and, if eligible, enrolled <4 months of age between 2004 and 2010 and then followed through December 2019 for this analysis. The study enrolled 8,676 children (89% general population, 11% first-degree relatives), of whom 832 developed islet autoimmunity. TEDDY defined autoantibody positive as positive for at least one autoantibody (GAD antibody [GADA], IA-2A, or insulin autoantibody [IAA]) on two consecutive visits confirmed by both TEDDY core laboratories (21). HbA<sub>1c</sub> was collected at first appearance of autoantibodies starting as early as the 12-month visit. HbA<sub>1c</sub> was collected every 3 months if the child remained autoantibody positive. Otherwise, if a child reverted to antibody negative for 12 months, collection of these measures stopped. OGTT was performed every 6 months in children with two or more autoantibodies starting at age 3 years. The OGTT 2-h plasma glucose (2-hPG), the part of the OGTT typically used to assess glucose tolerance, is evaluated as a prognostic comparison with relative change in HbA<sub>1c</sub> on risk of stage 3 in a subgroup of children who had both HbA<sub>1c</sub> and OGTT measures available.

### TrialNet Study

From February 2004 through December 2012, the TrialNet study screened islet autoantibodies in 112,280 individuals with a relative with type 1 diabetes. If an individual is positive for GADA, IAA, or IA-2A, they are tested for cytoplasmic islet cell antibodies and zinc transporter 8 autoantibodies (available from 2012 onward) on the same sample. After confirmation of

autoantibody positivity and based on number of autoantibodies, participants are assessed every 6–12 months, which includes HbA<sub>1c</sub> and repeat autoantibody testing. All assays were performed at a central core laboratory (22).

### HbA<sub>1c</sub> Measurement

TEDDY and TrialNet use a single core laboratory to measure HbA<sub>1c</sub> using the NGSP-certified method. TEDDY samples were tested at the Diagnostic Diabetes Laboratory in Columbia, MO. TrialNet samples were processed at the Northwest Lipids Research Laboratory in Seattle, WA. Both laboratories measured HbA<sub>1c</sub> using ion-exchange high-performance liquid chromatography with G7 and G8 auto-analyzers (TOSOH Bioscience, San Francisco, CA) standardized using the Diabetes Control and Complications Trial reference method (imprecision coefficient of variation <1.3%). For local collection at diagnosis, the U.S. and Canadian NGSP reference ranges and most European sites used International Federation of Clinical Chemistry and Laboratory Medicine or DCCT ranges. The Swedish (SWE) clinical centers used the Mono S normal ranges or International Federation of Clinical Chemistry and Laboratory Medicine reference ranges. These measures were converted to NGSP reference ranges for comparison in the analyses (SWE Mono S: NGSP% =  $[0.923 \times \text{SWE}\%] + 1.345$ ) (25).

### Statistical Analysis

We assessed a relative change in HbA<sub>1c</sub> from a baseline measure taken within 3 months after a child first seroconverted to positivity for islet autoantibody(s) in TEDDY or from the time of first HbA<sub>1c</sub> measure (baseline) in TrialNet. Mann-Whitney *U* tests compared median values. Kaplan-Meier curves depict proportions reaching a specific relative change in HbA<sub>1c</sub> and proportions, with or without stage 3. Multivariable Cox proportional hazards models assessed known risk factors associated with specific relative changes from baseline in HbA<sub>1c</sub> (5, 10, or 20%). We evaluated known risk factors, including family history of type 1 diabetes (father, mother, or sibling), HLA DR3/4 or other genotype, age at baseline HbA<sub>1c</sub> visit, HbA<sub>1c</sub> value at baseline visit, genetic sex, number of autoantibodies at time of relative change in HbA<sub>1c</sub>, first-appearing IAA versus GADA, and maximum rate of

HbA<sub>1c</sub> change and interactive effects. The maximum rate of change in relative HbA<sub>1c</sub> from baseline was defined as the greatest percent HbA<sub>1c</sub> change between consecutive HbA<sub>1c</sub> measures up to the time when the overall HbA<sub>1c</sub> change threshold percentage was achieved over time from baseline. Number of autoantibodies was calculated as the maximum number of autoantibodies up to the specific percentage change in HbA<sub>1c</sub>. Multivariable Cox proportional hazards models evaluated the risk of stage 3 based on whether or not a specified relative change in HbA<sub>1c</sub> was reached. These models were adjusted for age at HbA<sub>1c</sub> baseline visit, HbA<sub>1c</sub> baseline value, maximum rate of change, and number of autoantibodies by the time the HbA<sub>1c</sub> increase was achieved. Family history of type 1 diabetes, sex, and HLA DR3/DR4 genotype were assessed as binary variables. Receiver operating characteristic (ROC) curves reveal the prognostic performance of a relative change in HbA<sub>1c</sub> or OGTT 2-hPG. Optimal thresholds for relative change in HbA<sub>1c</sub> and OGTT 2-hPG were identified using the Youden index (i.e., maximum of the sum of the sensitivity and specificity) (26). Prognostic composite scores consisting of specific associated risk factors, including the threshold of  $\geq 10\%$  HbA<sub>1c</sub> increase or OGTT 2-hPG  $\geq 8$  mmol/L on the risk of stage 3 were evaluated by time-varying ROC models using the inverse probability of censoring weighting method from the time of meeting the threshold or baseline value if the threshold is unmet. External validation of a  $\geq 10\%$  increase in HbA<sub>1c</sub> from the baseline collected HbA<sub>1c</sub> on risk of stage 3 used the TrialNet study. Data were analyzed on SAS 9.4 software (SAS Institute, Cary, NC) and GraphPad Prism 7.04 (GraphPad Software, San Diego, CA) was used for figures. Two-tailed *P* values <0.05 were considered significant.

### RESULTS

This analysis includes 707 TEDDY participant children who met the inclusion criteria as of 31 December 2019. The median age at diagnosis or last visit was 11.1 (interquartile range 9.0–12.8) years. Of these 707 children, 304 (43.0%) remained single-autoantibody positive throughout the follow-up and 403 (57.0%) developed multiple autoantibodies. During follow-up, 235 (33.2%) developed stage 3 (213 [52.9%] from the group with multiple

autoantibodies and 22 [7.2%] from those with a single autoantibody). Characteristics by stage 3 status are summarized for TEDDY participants in Supplementary Table 1.


In similar fashion, 1,190 TrialNet youth who met the inclusion criteria as of 31 December 2012 are included in this analysis. The median age at diagnosis or last visit was 12.95 years. During follow-up, 193 (16.2%) developed clinical type 1 diabetes (180 [21.6%] from those with multiple autoantibodies [*n* = 834] and 13 [3.7%] from those with a single autoantibody [*n* = 356]). Characteristics of these TrialNet participants are reported in Supplementary Table 2.

### Determining Optimum Size of HbA<sub>1c</sub> Percentage Increase and OGTT 2-hPG Level to Predict Stage 3 in TEDDY

Using only the glycemic measure itself in ROC curve analysis, the most predictive overall extent of HbA<sub>1c</sub> increase from baseline was found to be 10% based on maximizing the Youden *J* statistic (Fig. 1A). This increase was 73.6% sensitive and 88.3% specific to mark future stage 3 occurring during follow-up observation. The positive predictive value (PPV) was 76%. In a similar manner, for the OGTT, the most predictive 2-hPG level was  $\geq 8$  mmol/L, 73.0% sensitive and 82.4% specific with a PPV of 79%, to mark future stage 3 occurring during follow-up observation (Fig. 1B).

### Factors Associated With a $\geq 10\%$ Relative Change in Percent HbA<sub>1c</sub>

We next sought to identify diabetes-related primary risk factors significantly associated with an increase in HbA<sub>1c</sub> from baseline (Supplementary Table 3). An older age at the baseline test was associated with a decreased risk of achieving a  $\geq 10\%$  increase in HbA<sub>1c</sub> for both studies (hazard ratio [HR] 0.92, overall *P* < 0.014). Further, a lower HbA<sub>1c</sub> level at the baseline test was associated with an increased risk of achieving a  $\geq 10\%$  increase in HbA<sub>1c</sub> (*P* < 0.0001 for both studies). The risk of a relative change in HbA<sub>1c</sub> also increased with a greater number of autoantibodies present by the time that the  $\geq 10\%$  HbA<sub>1c</sub> increase was achieved (TEDDY: HR 1.87, 95% CI 1.6–2.2, *P* < 0.0001; TrialNet: HR 1.97, 95% CI 1.6–2.5, *P* < 0.0001). A greater maximum rate of change between repeated HbA<sub>1c</sub> measures from baseline



**Figure 1**—Identification of optimal thresholds and evaluation of percent HbA<sub>1c</sub> increase from baseline HbA<sub>1c</sub> (A) and OGTT 2-hPG (B) optimal thresholds as a prognostic for progression to type 1 diabetes in the TEDDY children. For the HbA<sub>1c</sub>,  $n = 707$  and for the OGTT  $n = 426$ . NPV, negative predictive value.


increased the risk of a  $\geq 10\%$  change in HbA<sub>1c</sub> ( $P < 0.0001$  for both studies). For unknown reasons, female children had a lower likelihood of HbA<sub>1c</sub> risk in TEDDY (HR 0.72, 95% CI 0.6–0.9,  $P = 0.009$ ), but not in TrialNet. Having a family history of type 1 diabetes was not associated with an HbA<sub>1c</sub> change ( $P = 0.39$ ). We also explored interactions of the above factors and found that a younger age at the HbA<sub>1c</sub> baseline test significantly interacted with a greater number of autoantibodies to augment the risk of a  $\geq 10\%$  increase in HbA<sub>1c</sub> from baseline in TEDDY children (HR 1.10, 95% CI 1.0–1.2,  $P = 0.021$ ) (Supplementary Fig. 1). Finally, we assessed whether having a first-appearing IAA versus GADA associated with a change in HbA<sub>1c</sub> and found no significant association in TEDDY ( $P = 0.37$ ). Survival curves depicting the rate of achievement from time of seroconversion for 5%, 10%, and 20% overall increases in HbA<sub>1c</sub> from baseline measurement are shown in Supplementary Fig. 2.

### Change in HbA<sub>1c</sub> Predicted Risk of Stage 3 in Youth

We used the identified optimum HbA<sub>1c</sub> percentage increase (Fig. 1) in TEDDY adjusted for the factors that modify this change (Supplementary Table 3) in multivariable Cox proportional hazards models

evaluating a  $\geq 10\%$  HbA<sub>1c</sub> increase in TEDDY and TrialNet on risk of stage 3. Survival curves from this model applied to both studies are shown in Fig. 2. The multivariable model featuring a  $\geq 10\%$

increase in HbA<sub>1c</sub> revealed a markedly increased risk of stage 3 in both TEDDY (HR 12.74, 95% CI 8.7–18.6,  $P < 0.0001$ ) and TrialNet (HR 5.09, 95% CI 3.3–7.9,  $P < 0.0001$ ). We found that the



**Figure 2**—Multivariable Cox proportional hazards models evaluating  $\geq 10\%$  HbA<sub>1c</sub> increase in TEDDY and TrialNet on progression to type 1 diabetes from time at  $\geq 10\%$  increase in HbA<sub>1c</sub>. Reference is  $<10\%$  HbA<sub>1c</sub> increase. Models adjusted for age at HbA<sub>1c</sub> baseline, HbA<sub>1c</sub> baseline measure, number of autoantibodies at time of HbA<sub>1c</sub> change, maximum rate of change from baseline, and genetic sex. A  $\geq 10\%$  increase in HbA<sub>1c</sub> increases the risk of progression to type 1 diabetes in both the TEDDY (HR 12.74, 95% CI 8.7–18.6,  $P < 0.0001$ ) and TrialNet (HR 5.09, 95% CI 3.3–7.9,  $P < 0.0001$ ) studies.



maximum rate of change between HbA<sub>1c</sub> measures leading up to and including the visit at which the 10% threshold was met is associated with an increased risk of stage 3 (TEDDY: HR 1.34, 95% CI 1.2–1.5,  $P < 0.0001$ ; TrialNet: HR 1.24, 95% CI 1.2–1.3,  $P < 0.0001$ ). The median (interquartile range) years from the time the child had an HbA<sub>1c</sub>  $\geq 10\%$  increase and progressed to stage 3 was 0.70 (0.2–1.7) in TEDDY and 0.16 (0.02–0.50) in TrialNet. In TEDDY, an older age at meeting the percent HbA<sub>1c</sub> increase was associated with a lower risk of progressing within 2 years. Corresponding results for an overall 5%, 10%, or 20% HbA<sub>1c</sub> increase are shown in Supplementary Fig. 3.

#### A Change in Percent HbA<sub>1c</sub> Is as Good a Predictor of Future Stage 3 in a Young Population With Multiple Islet Autoantibodies As a Single OGTT 2-hPG


In TEDDY, the OGTT 2-hPG is measured only in children with multiple autoantibodies older than age 3, while HbA<sub>1c</sub> is measured in those with any autoantibody. For this analysis, 426 children who had both HbA<sub>1c</sub> and OGTT recorded are included. Most without an OGTT had

only one autoantibody ( $n = 245$ ), while 10 children were  $< 3$  years old and the remaining 26 did not have both measures available. The utility of a percentage increase in HbA<sub>1c</sub> over baseline performed well as a prognostic measure in a young population, with an ROC area under the curve (AUC) of 0.825, essentially the same as the OGTT 2-hPG with an ROC AUC of 0.824 (Fig. 3A). Overall, 79% ( $n = 161$  of 204) of the TEDDY children who had a  $\geq 10\%$  HbA<sub>1c</sub> increase and 77% ( $n = 156$  of 204) of those who had an OGTT 2-hPG  $\geq 8$  mmol/L developed stage 3 diabetes (Fig. 4). Given this, we developed a composite score for each of these measures to evaluate whether the performance could be improved. The time-varying ROC AUC performance of both the composite HbA<sub>1c</sub>  $\geq 10\%$  increase model and the composite OGTT 2-hPG  $\geq 8$  mmol/L model were then determined for a range of time horizons summarized graphically in Fig. 3B, again showing remarkably comparable results over a wide range of time horizons (TEDDY integrated AUCs of 0.88 and 0.85, respectively). The composite score for HbA<sub>1c</sub>  $\geq 10\%$  included whether or not threshold was met, age and HbA<sub>1c</sub> at baseline measure, number of autoantibodies at time of HbA<sub>1c</sub> change,


and maximum rate of change up to HbA<sub>1c</sub>  $\geq 10\%$  increase. The composite score for OGTT 2-hPG  $\geq 8$  mmol/L included whether or not the threshold was met, OGTT 2-hPG value at baseline, age when the threshold was met, family history of type 1 diabetes, and genetic sex. Assessment of known diabetes risk factors associated with a rise in OGTT  $\geq 8$  mmol/L are reported in Supplementary Table 4. These ROC AUC values were stable over a variety of time horizons after the glycemic criterion was achieved (Fig. 3B). The HbA<sub>1c</sub> composite model performed equally well in the TrialNet population with an integrated AUC of 0.82 over 5-year horizons.

#### CONCLUSIONS

While the pathophysiology of type 1 diabetes is still not well understood, it is clear that stage 3 is heterogenous and associated with many factors. The time to stage 3 may be many years, and a practical, efficient way to monitor progression is an essential need. Monitoring HbA<sub>1c</sub> over time is a promising early indicator to assess escalating risk in individuals at high-risk for type 1 diabetes from both the general population and those with a family history. Our findings



**Figure 3**—Evaluating the utility of percent HbA<sub>1c</sub> increase and OGTT 2-hPG as prognostic measures on predicting progression of type 1 diabetes in a subset of TEDDY children with both percent HbA<sub>1c</sub> change and OGTT data available ( $n = 426$ ) (A) and composite score performance over increasing follow-up horizons (B). The composite score for HbA<sub>1c</sub>  $\geq 10\%$  included whether or not the 10% increase in HbA<sub>1c</sub> was achieved, the baseline HbA<sub>1c</sub> value, the age at baseline HbA<sub>1c</sub>, the maximum number of autoantibodies by time of the HbA<sub>1c</sub> change, and maximum rate of change through the time of the HbA<sub>1c</sub>  $\geq 10\%$  increase. Composite score for OGTT  $\geq 8$  mmol/L included whether or not the threshold was met, OGTT 2-hPG value at baseline, family history of type 1 diabetes, and genetic sex. Only significant covariates are included in the composite score models.



**Figure 4**—Venn diagram of the TEDDY children who met the HbA<sub>1c</sub> ≥ 10% threshold and/or OGTT 2-hPG ≥ 8 mmol/L threshold ( $n = 286/426$ ) and progressed to stage 3 ( $n = 204$ ).

show that a relative increase of ≥10% in HbA<sub>1c</sub> from baseline is as informative as OGTT 2-hPG in predicting risk of stage 3 in youth. Moreover, combined with age at the first HbA<sub>1c</sub> test (related to age at seroconversion), baseline HbA<sub>1c</sub> level, maximum rate of HbA<sub>1c</sub> change, and number of islet autoantibodies, achieving a 10% increase from the baseline HbA<sub>1c</sub> fits into a highly predictive composite model estimating risk of stage 3, with similar performance to a corresponding composite OGTT-based model. Periodic autoantibody surveillance of children with islet autoantibodies, including an HbA<sub>1c</sub> measurement at each sampling, may be sufficient to estimate timing of onset within 2 years in most cases and requires no additional sampling by the clinician.

HbA<sub>1c</sub> is among the 10 most common clinical laboratory tests performed in the U.S. (27). For HbA<sub>1c</sub> measurements, the total allowable error currently ranges from ±5% (NGSP) to ±6% (College of American Pathologists), although a loosening of this requirement has been proposed (28). Direct comparisons of point-of-care testing to laboratory testing showed a mean relative difference of 2.1%, suggesting both point-of-care and laboratory-based tests can be quite precise and comparable (29), although variation in testing site or method could contribute to observed HbA<sub>1c</sub> changes. In addition to variation in measurement, individual physiological variations in HbA<sub>1c</sub> can result from increased red cell turnover (30) due to a number of

hereditary, autoimmune, infectious, or chemical causes. A small variation of HbA<sub>1c</sub> with season (amplitude 0.2–0.3%) has been described in many published studies over the last 25 years (31). Irrespective of blood glucose levels, a decrease in hemoglobin or iron, such as that caused by aberrant erythropoiesis, reduced iron absorption, or increased loss, has been associated with an increased HbA<sub>1c</sub> level (32). Finally, several genetic loci are known to be associated with HbA<sub>1c</sub> levels (33). Many of these loci are not associated with blood glucose levels, although their associations with hemolysis, erythropoiesis, or seasonal changes in physiology are not known.

When compared with OGTT, a single measure of HbA<sub>1c</sub> was as predictive of type 2 diabetes as fasting plasma glucose or the OGTT 2-hPG in American Indian individuals 10–39 years of age in the Southwestern U.S. (34). Even in children, OGTT is not always clearly better than HbA<sub>1c</sub> and especially CGM (18). However, for diabetes staging in large well-managed pediatric prediction studies, OGTT has provided very good predictive power (35,36). OGTT provides prognostic results from just one test, while the current HbA<sub>1c</sub> method requires the additional information provided by sequential measurements. Yet, the OGTT test is challenging to perform in a primary care clinical setting or remotely by patient and family; whereas, HbA<sub>1c</sub> is readily measured from one low-volume clinical or home sampling. Importantly,

HbA<sub>1c</sub> is an extremely common and accessible clinical test with modest cost and greater patient and provider familiarity than CGM or OGTT testing. In the setting of surveillance of islet autoantibody-positive children, often with stage 1 diabetes (37), quarterly blood sampling that adds HbA<sub>1c</sub> testing to islet autoantibody testing is also reasonable from a logistical perspective. These children are at high risk of dysglycemia, and we believe they warrant such surveillance requiring overall blood draw volumes of <1 mL every 3 months. Our results suggest that HbA<sub>1c</sub> monitoring can predict stage 3 with sufficient lead time for education and closer monitoring for earlier detection of metabolic decompensation. While a simple 10% rise from baseline in HbA<sub>1c</sub> would be readily apparent to a clinician, obtaining a more accurate prognosis using the composite score might be facilitated by access to a simple and quick way to enter and use sequential HbA<sub>1c</sub> and islet autoantibody results. A web-based application with a calculator format, for example, that is used for monogenic diabetes (38,39), could rapidly provide clinically interpretable prognostic information in those with genetic and familial risk screened for islet autoantibodies. In those who achieve this HbA<sub>1c</sub> prognostic increase, the close monitoring of impending diabetes may then be an ideal setting for CGM (15,18) where ≥18% time spent at >140 mg/dL was shown to have a 100% PPV (15).

This study's strength is that TEDDY and TrialNet are large, prospective studies that collect metabolic measures on individuals at high genetic or familial risk of type 1 diabetes either quarterly in TEDDY or every 6–12 months in TrialNet. The short interval of collection in TEDDY provides an especially precise understanding of the variation of these measures across time and leading up to onset.

Yet, this analysis has some limitations. One is that our study population is at high genetic or familial risk. Although most TEDDY children are from the general population, even those are selected from HLA genotypes that only account for 50% of general population type 1 diabetes cases. There are limits to generalizing these findings to all populations as these children are selected for elevated genetic or familial risk before further evaluation, which is typical of those

who would be screened for interventional trials and observational studies. As with all predictive testing, consideration should be given to justifying screening programs for clinical use with focus on psychological impacts and long-term consequences (40). TEDDY did not start HbA<sub>1c</sub> testing until late 2009, which was two-thirds of the way through TEDDY recruitment. Because of this and also because stage 3 is less common in infants and toddlers, fewer such cases were analyzed, and the results are less certain for very young onsets. Like any measure of glycemia, HbA<sub>1c</sub> reflects not only  $\beta$ -cell function but also insulin sensitivity, as reflected by BMI, dietary choices, activity level, and ancestry, etc. The current participants in TEDDY were mostly prepubertal, a time when insulin sensitivity is generally high, so that elevated HbA<sub>1c</sub> might be more reflective of endogenous insulinopenia. Our results must therefore be confirmed in studies of postpubertal onsets, albeit with care to differentiate type 1 prediabetes from type 2 prediabetes. Although ~7% of TEDDY children were of African, Asian, or Hispanic ancestry (primarily from the U.S. sites), most were of European descent, and results should be confirmed in settings of more diverse ancestry. Finally, stage 3 was ascertained more promptly under the TEDDY and TrialNet protocols (often through OGTT or home SMBG) than might be expected during routine medical care, although not more promptly than what might be achieved by the ongoing glycemic surveillance that our approach implies.

Here, we show that change in HbA<sub>1c</sub> is a useful noninvasive measure to predict the likelihood of stage 3 in a young population. Such HbA<sub>1c</sub> surveillance might be part of a sequential multitiered approach consisting of 1) genetic screening at birth; 2) subsequent islet autoantibody cross-sectional screening with confirmation of positive results; 3) ongoing islet autoantibody and HbA<sub>1c</sub> surveillance and parental education in those with confirmed islet autoantibod(ies); and 4) heightened glycemic surveillance (e.g., CGM or OGTT) and/or referral to immunotherapy trials in those that met the HbA<sub>1c</sub> threshold during surveillance testing. Tier 3 above represents simpler glycemic surveillance than that specified in TEDDY or TrialNet protocols. This may improve compliance and lower costs to

translate better to general medical care settings while preserving early diagnosis, lowered morbidity from diabetic ketoacidosis at onset, and opportunities for intervention therapy.

**Acknowledgments.** The authors acknowledge the support of the Type 1 Diabetes TrialNet Study Group's Pathway to Prevention Study. The authors thank Sarah Austin-Gonzalez with the Health Informatics Institute at the University of South Florida for assistance with preparing the figures. A special acknowledgment to the TEDDY families for their continued participation in this wonderful study.

**Funding.** The TEDDY Study is funded by National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases U01 DK63829, U01 DK63861, U01 DK63821, U01 DK63865, U01 DK63863, U01 DK63836, U01 DK63790, UC4 DK63829, UC4 DK63861, UC4 DK63821, UC4 DK63865, UC4 DK63863, UC4 DK63836, UC4 DK95300, UC4 DK100238, UC4 DK106955, UC4 DK112243, UC4 DK117483, U01 DK124166, U01 DK128847, and contract no. HSN267200700014C, the National Institute of Allergy and Infectious Diseases, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institute of Environmental Health Sciences, Centers for Disease Control and Prevention, and JDRF. This work is supported in part by the National Institutes of Health/National Center for Advancing Translational Sciences Clinical and Translational Science Awards to the University of Florida (UL1 TR000064) and the University of Colorado (UL1 TR002535).

The Type 1 Diabetes TrialNet Study Group is a clinical trials network funded by the National Institutes of Health through the National Institute of Diabetes and Digestive and Kidney Diseases (U01 DK106993) the National Institute of Allergy and Infectious Diseases, and the Eunice Kennedy Shriver National Institute of Child Health and Human Development, through cooperative agreements, and the JDRF.

The contents of this article are solely the responsibility of the authors and do not necessarily represent the official views of the National Institutes of Health or the JDRF.

**Duality of Interest.** No potential conflicts of interest relevant to this article were reported.

**Author Contributions.** K.V. and D.B. researched and analyzed the data. K.V. and W.H. evaluated the data, wrote the manuscript, and reviewed and edited the manuscript. M.K., M.R., R.M.I., J.T., Å.L., B.A., H.R., D.A.S., A.-G.Z., and J.P.K. reviewed and edited the manuscript. K.V., M.R., R.M.I., J.T., Å.L., B.A., H.R., D.A.S., A.-G.Z., and J.P.K. reviewed and edited the manuscript. K.V. is the guarantor of this work, and as such, has full access to all the data in the study and takes responsibility for the integrity of data and the accuracy of data analysis.

**Prior Presentation.** This work was presented at the 80th Scientific Sessions of the American Diabetes Association, virtual meeting, 12–16 June 2020.

## References

1. Mayer-Davis EJ, Dabelea D, Lawrence JM. Incidence trends of type 1 and type 2 diabetes among youths, 2002–2012. *N Engl J Med* 2017; 377:301
2. Krischer JP, Liu X, Lernmark Å, et al.; TEDDY Study Group. The influence of type 1 diabetes genetic susceptibility regions, age, sex, and family history on the progression from multiple autoantibodies to type 1 diabetes: a TEDDY study report. *Diabetes* 2017;66:3122–3129
3. Ziegler AG, Rewers M, Simell O, et al. Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children. *JAMA* 2013;309:2473–2479
4. Hagopian WA, Sanjeevi CB, Kockum I, et al. Glutamate decarboxylase-, insulin-, and islet cell-antibodies and HLA typing to detect diabetes in a general population-based study of Swedish children. *J Clin Invest* 1995;95:1505–1511
5. Elding Larsson H, Vehik K, Bell R, et al.; TEDDY Study Group; SEARCH Study Group; Swediabkids Study Group; DPV Study Group; Finnish Diabetes Registry Study Group. Reduced prevalence of diabetic ketoacidosis at diagnosis of type 1 diabetes in young children participating in longitudinal follow-up. *Diabetes Care* 2011;34: 2347–2352
6. Everett EM, Copeland TP, Moin T, Wisk LE. National trends in pediatric admissions for diabetic ketoacidosis, 2006–2016. *J Clin Endocrinol Metab* 2021;106:2343–2354
7. Steck AK, Vehik K, Bonifacio E, et al.; TEDDY Study Group. Predictors of progression from the appearance of islet autoantibodies to early childhood diabetes: The Environmental Determinants of Diabetes in the Young (TEDDY). *Diabetes Care* 2015;38:808–813
8. Bonifacio E. Predicting type 1 diabetes using biomarkers. *Diabetes Care* 2015;38:989–996
9. Ilonen J, Hammal A, Laine AP, et al. Patterns of  $\beta$ -cell autoantibody appearance and genetic associations during the first years of life. *Diabetes* 2013;62:3636–3640
10. Wesley JD, Pfeiffer S, Schneider D, et al. Peripheral autoreactive CD8 T-cell frequencies are too variable to be a reliable predictor of disease progression of human type 1 diabetes. *Clin Transl Immunology* 2021;10:e1309
11. Lamichhane S, Kemppainen E, Tröst K, et al. Circulating metabolites in progression to islet autoimmunity and type 1 diabetes. *Diabetologia* 2019;62:2287–2297
12. Steele C, Hagopian WA, Gitelman S, et al. Insulin secretion in type 1 diabetes. *Diabetes* 2004;53:426–433
13. Helminen O, Aspholm S, Pokka T, et al. OGTT and random plasma glucose in the prediction of type 1 diabetes and time to diagnosis. *Diabetologia* 2015;58:1787–1796
14. American Diabetes Association Professional Practice Committee. 2. Classification and diagnosis of diabetes: *Standards of Medical Care in Diabetes—2022*. *Diabetes Care* 2022;45:S17–S38
15. Steck AK, Liu X, Krischer JP, et al. Factors associated with the decline of C-peptide in a cohort of young children diagnosed with type 1 diabetes. *J Clin Endocrinol Metab* 2021;106: e1380–e1388
16. Vehik K, Cuthbertson D, Boulware D, et al.; TEDDY, TRIGR, Diabetes Prevention Trial–Type 1,

- and Type 1 Diabetes TrialNet Natural History Study Groups. Performance of HbA<sub>1c</sub> as an early diagnostic indicator of type 1 diabetes in children and youth. *Diabetes Care* 2012;35:1821–1825
17. Stene LC, Barriga K, Hoffman M, et al. Normal but increasing hemoglobin A<sub>1c</sub> levels predict progression from islet autoimmunity to overt type 1 diabetes: Diabetes Autoimmunity Study in the Young (DAISY). *Pediatr Diabetes* 2006;7:247–253
  18. Helminen O, Pokka T, Tossavainen P, Ilonen J, Knip M, Veijola R. Continuous glucose monitoring and HbA<sub>1c</sub> in the evaluation of glucose metabolism in children at high risk for type 1 diabetes mellitus. *Diabetes Res Clin Pract* 2016;120:89–96
  19. Helminen O, Aspholm S, Pokka T, et al. HbA<sub>1c</sub> predicts time to diagnosis of type 1 diabetes in children at risk. *Diabetes* 2015;64:1719–1727
  20. Ludvigsson J, Cuthbertson D, Becker DJ, et al.; TRIGR Investigators. Increasing plasma glucose before the development of type 1 diabetes—the TRIGR study. *Pediatr Diabetes* 2021;22:974–981
  21. Rewers M, Hyöty H, Lernmark Å, et al.; TEDDY Study Group. The Environmental Determinants of Diabetes in the Young (TEDDY) Study: 2018 update. *Curr Diab Rep* 2018;18:136
  22. Mahon JL, Sosenko JM, Rafkin-Mervis L, et al.; TrialNet Natural History Committee; Type 1 Diabetes TrialNet Study Group. The TrialNet natural history study of the development of type 1 diabetes: objectives, design, and initial results. *Pediatr Diabetes* 2009;10:97–104
  23. TEDDY Study Group. The Environmental Determinants of Diabetes in the Young (TEDDY) Study. *Ann N Y Acad Sci* 2008;1150:1–13
  24. Hagopian WA, Erlich H, Lernmark A, et al.; TEDDY Study Group. The Environmental Determinants of Diabetes in the Young (TEDDY): genetic criteria and international diabetes risk screening of 421 000 infants. *Pediatr Diabetes* 2011;12:733–743
  25. Hoelzel W, Weykamp C, Jeppsson JO, et al.; IFCC Working Group on HbA<sub>1c</sub> Standardization. IFCC reference system for measurement of hemoglobin A<sub>1c</sub> in human blood and the national standardization schemes in the United States, Japan, and Sweden: a method-comparison study. *Clin Chem* 2004;50:166–174
  26. Youden WJ. Index for rating diagnostic tests. *Cancer* 1950;3:32–35
  27. Horton S, Fleming KA, Kuti M, et al. The top 25 laboratory tests by volume and revenue in five different countries. *Am J Clin Pathol* 2019;151:446–451
  28. Klonoff DC, Aron D, Cohen RM, et al. The need for accuracy in hemoglobin A<sub>1c</sub> proficiency testing: why the proposed CLIA rule of 2019 is a step backward. *J Diabetes Sci Technol* 2019;13:424–427
  29. Nathan DM, Griffin A, Perez FM, Basque E, Do L, Steiner B. Accuracy of a point-of-care hemoglobin A<sub>1c</sub> assay. *J Diabetes Sci Technol* 2019;13:1149–1153
  30. Cohen RM, Franco RS, Khera PK, et al. Red cell life span heterogeneity in hematologically normal people is sufficient to alter HbA<sub>1c</sub>. *Blood* 2008;112:4284–4291
  31. Tseng CL, Brimacombe M, Xie M, et al. Seasonal patterns in monthly hemoglobin A<sub>1c</sub> values. *Am J Epidemiol* 2005;161:565–574
  32. Coban E, Ozdogan M, Timuragaoglu A. Effect of iron deficiency anemia on the levels of hemoglobin A<sub>1c</sub> in nondiabetic patients. *Acta Haematol* 2004;112:126–128
  33. Soranzo N, Sanna S, Wheeler E, et al. Common variants at 10 genomic loci influence hemoglobin A<sub>1c</sub> levels via glycemic and non-glycemic pathways [published correction appears in *Diabetes* 2011;60:1050–1051 multiple author names added] *Diabetes* 2010;59:3229–3239
  34. Vijayakumar P, Nelson RG, Hanson RL, Knowler WC, Sinha M. HbA<sub>1c</sub> and the prediction of type 2 diabetes in children and adults. *Diabetes Care* 2017;40:16–21
  35. Sosenko JM, Palmer JP, Rafkin-Mervis L, et al.; Diabetes Prevention Trial-Type 1 Study Group. Incident dysglycemia and progression to type 1 diabetes among participants in the Diabetes Prevention Trial-Type 1. *Diabetes Care* 2009;32:1603–1607
  36. Sosenko JM, Skyler JS, Mahon J, et al.; Type 1 Diabetes TrialNet Study Group; Diabetes Prevention Trial-Type 1 Study Group. The application of the Diabetes Prevention Trial-Type 1 risk score for identifying a preclinical state of type 1 diabetes. *Diabetes Care* 2012;35:1552–1555
  37. Insel RA, Dunne JL, Atkinson MA, et al. Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association. *Diabetes Care* 2015;38:1964–1974
  38. Shields BM, McDonald TJ, Ellard S, Campbell MJ, Hyde C, Hattersley AT. The development and validation of a clinical prediction model to determine the probability of MODY in patients with young-onset diabetes. *Diabetologia* 2012;55:1265–1272
  39. MODY Probability Calculator. Accessed 18 August 2022. Available from <https://www.diabetesgenes.org/exeter-diabetes-app/modycalculator>
  40. Ludvigsson J. When is screening for type 1 diabetes in children justified? *J Pediatr Neonatol* 2021;2:17–19